Navigation Links
Dendreon Announces Presentation of Data at American Urological,Association Annual Meeting

-Data May Support Use of Provenge as Front-line Treatment in Advanced Prostate Cancer-

SEATTLE and ANAHEIM, Calif., May 20, 2007 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced the presentation of data from an analysis of Phase 3 Studies (D9901 and D9902A) that showed a prolonged survival benefit for patients who were initially treated with Provenge (sipuleucel-T) who then went on to receive docetaxel chemotherapy after disease progression. The data were presented today at the American Urological Association (AUA) Annual Meeting in Anaheim, California.

The abstract, titled "Advanced Prostate Cancer Patients who Receive Sipuleucel-T followed by Docetaxel Have Prolonged Survival" (#605), authored by Daniel P. Petrylak, M.D., associate professor of medicine at New York- Presbyterian Hospital at the Medical Center, is based on an exploratory analysis conducted to assess the influence of the active cellular immunotherapy PROVENGE on the clinical outcome of patients who subsequently went on to receive docetaxel chemotherapy after primary treatment with PROVENGE. The analysis was conducted by evaluating data from two Phase 3 clinical trials of PROVENGE in patient with asymptomatic, metastatic, androgen-independent prostate cancer (AIPC).

"The results of this analysis suggest that the use of sipuleucel-T as a first-line treatment followed by the chemotherapy docetaxel upon disease progression may provide patients with a substantially prolonged survival benefit," said Dr. Petrylak. "This analysis provides valuable clinical insight as to how the treatment of men with advanced prostate cancer will likely evolve with the potential introduction of new products like sipuleucel- T that complement the currently available treatment regimens for men with advanced prostate cancer."

Study Design and Results

This analysis was conducted by evaluating data from two identically designed rando
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/29/2014)...  Encision Inc. (OTCQB:ECIA), a medical device company owning ... in minimally invasive surgery, today announced financial results for ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $311 thousand, or $(0.04) per share, in the ...
(Date:7/29/2014)... , July 29, 2014   ... announced that it has taken an exclusive worldwide licence ... Ltd, a Durham University spin-out ... will pay an upfront fee, development and commercial milestone ... has also taken an option for additional exclusive licences ...
(Date:7/28/2014)... July 28, 2014  Dignity Health St. Mary,s ... the Get With The Guidelines®-Stroke Silver-Plus Quality Achievement ... by the American Heart Association/American Stroke Association for ... number four cause of death and a leading ... United States , according to the American ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
(Date:7/29/2014)... 2014 This month, Therapy Changes ... to a Successful, Balanced Career.” The guide is geared ... seeking guidance on creating a successful career. , ... focus, determination, and understanding your strengths and limits,” says ... guide will uncover the elements to creating balance in ...
(Date:7/29/2014)... 29, 2014 Premier Women’s Health ... Moon Township areas, has affiliated with Allegheny Health Network’s ... continue to deliver babies and perform surgical procedures at ... care will be referred to Allegheny Health Network’s ... be associated with West Penn Hospital and its highly ...
(Date:7/29/2014)... Regents Health Resources, a consulting firm ... health care industry veteran Daryl Demonbreun and former St. ... the company’s ambitious plans to grow into a full-service ... moving along at a steady pace for nearly 20 ... notch,” says Bob Maier, founder and chief executive officer ...
(Date:7/29/2014)... 2014 This Latest Guidebook for Conducting ... (2014 Edition) not only provided a comprehensive and thorough ... for imported drug registration but also introduced the practical ... guide you to use the Chinese trial venues to ... world step by step. , The audiences of this ...
(Date:7/29/2014)... (CA) method is in principle suitable to find out ... widely use it in health economic evaluations, some (primarily ... the result of a pilot project by the German ... Following the Analytic Hierarchy Process (AHP), CA is the ... experts. , Summarize outcome-specific results to an overall ...
Breaking Medicine News(10 mins):Health News:Therapy Changes Releases New Guide to Building a Successful Career 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 3Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4
... may be an effective treatment for patients with a ... which was focused on the mechanism by which an ... important role because it suggests that changes in light ... inhibits mating of the C. neoformans -- a potentially ...
... risk of vertebral bone fractures in women with low bone ... 55 and 80 years with bone mineral density T scores ... women randomly received five milligrams of alendronate for two years ... placebo. ,The risk of vertebral fracture was significantly reduced ...
... and people without liver cancer found that diabetics are stand ... to the general population. ,After taking other factors into ... disease, researchers found diabetes nearly tripled the risk of liver ... factor for liver cancer, may be boosting the risk even ...
... be a treatment for life-threatening asthma (LTA) in children, according ... were treated with intravenous administration of sodium bicarbonate to reduce ... in LTA. , It was seen that in 17 ... was a decrease in blood carbon dioxide levels accompanied by ...
... the standard test to detect dementia so that it ... early. The test called National Institute //of Ageing's ... list (CWL) needs only ten minutes to administer. ... dementia as these stages often go undetected. They used ...
... as folate or a form of vitamin B. this vitamin if ... having a twin baby or to avoid //neural tube defect. A ... proof for this common belief. ,The study was conducted ... there are some countries were it is a common practice to ...
Cached Medicine News:
... Aplicare's saturated swabsticks are packaged in ... 4 inch swabstick is saturated with precisely ... The Gel Swabstick is saturated with a ... The gel is also approved for venipuncture ...
... BETADINE® Spray provides 5% ... pump spray. It delivers ... wounds too tender to ... and is indicated whenever ...
... that does not contain Alcohol. ... destroys over 99% of bacteria. ... of minor wounds, burns, cuts, ... personal utensils and tools. Prevents ...
BETADINE® Surgical Scrub is a microbicidal, sudsing cleanser that promptly kills most bacteria, fungi, viruses, protozoa and yeasts. It is indicated for hand hygiene, surgical hand-scrubbing, an...
Medicine Products: